« Return to News | Clinical Intelligence

QE3 clinical trial stopped

Friday, June 10, 2011 12:04 PM

According to the National Parkinson Foundation, the National Institute for Neurological Disease and Stroke (NINDS) has stopped the clinical trial of Coenzyme Q10, referred to as the QE3 study.

The study was designed to test whether fairly high doses of Coenzyme Q10 were effective in slowing the progression of Parkinson's disease, or neuroprotective. The investigators of the trial determined that there was neither a neuroprotective nor a symptomatic benefit of Coenzyme Q10 for people with early Parkinson's disease.

The Foundation said all trial participants have already been alerted, and that the open and forthright communications to both investigators and patients should serve as a model for future clinical trial communications.

According to the Foundation, there are currently several promising new therapeutic approaches that seek to better target symptoms and potentially slow the disease in clinical and pre-clinical development pipelines, including gene therapy, advances in DBS and infusion technology, drugs that target better control of motor symptoms, dyskinesias and cognitive symptoms, and novel pathways to slow the disease.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.